KDR and non-small cell lung carcinoma: At this time, in addition to chemotherapy, immunotherapy, and targeted therapies, VEGFR2 and VEGF inhibitors have shown proven efficacy in NSCLC treatment in stage IV disease in combination with chemotherapy and also have also shown promise when combined with immunotherapy [3,9].